The Impact of Liver Steatosis on Interleukin and Growth Factors Kinetics during Chronic Hepatitis C Treatment DOI Open Access
Leona Radmanić, Snježana Židovec Lepej,

Nikolina Salek

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(16), P. 4849 - 4849

Published: Aug. 16, 2024

Background/Objectives: Various biological response modifiers play important roles in the immunopathogenesis of chronic hepatitis C (CHC). While serum levels cytokines and growth factors change with disease severity treatment responses, impact concomitant liver steatosis on systemic inflammatory is largely unknown. The aim this study was to analyze characteristics kinetics profiles interleukins CHC patients steatotic (SLD). Methods: Serum concentrations 12 (IL-5, IL-13, IL-2, IL-6, IL-9, IL-10, IFN-γ, TNF-α, IL-17A, IL-17F, IL-4 IL-22) 6 (Angiopoietin-2, EGF, EPO, HGF, SCF, VEGF) were analyzed 56 at four time points (baseline, week 4, 8 SVR12) bead-based flow cytometry assay. Results: At baseline, SLD had significantly lower IL-13 IL-22 higher VEGF ANG. In a subgroup advanced fibrosis, linked IL-4, IL-5, HGH VEGF. Distinct cytokine during DAA observed, identified as main source variation for IL-22, Patients SVR12 HGF concentrations. Conclusions: associated distinct factor treatment, which might be capacity regeneration contribute fibrosis persistence.

Language: Английский

Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection DOI Creative Commons
Yu‐Ping Chang,

Chiuan-Bo Huang,

Jia‐Horng Kao

et al.

Journal of the Formosan Medical Association, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Limited data exists regarding the long-term serum ferritin dynamics following sustained virologic response (SVR12) and factors associated with trends in changes among patients undergoing treatment for hepatitis C virus (HCV). Serum levels were assessed biannually 1538 participants direct-acting antivirals (DAAs) or peginterferon plus ribavirin (PR) a median of follow-up 5.0 years after off-treatment week 12. We compared differences time-dependent slope coefficients interest using generalized estimating equations to identify predictors favorable evolution. Using univariable analysis, SVR12, aged ≤50 year, absence metabolic dysfunction-associated steatotic liver disease (MASLD), pre-treatment HCV RNA level ≤2,000,000 IU/mL Multivariable analysis showed that SVR12 (adjusted coefficient difference: 7.50 ng/mL/year [95% CI: 3.37 -11.63], p < 0.001) MASLD 4.16 7.91 -0.41], = 0.022) predicted Among achieving evolution was not affected by DAA PR (crude 3.33 12.78 6.12], 0.49). Absence 2.86 5.39 -0.33], 0.021). Patients irrespective types treatment, exhibited more those SVR12. may help improve

Language: Английский

Citations

1
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection DOI
Chen‐Hua Liu, Pin‐Nan Cheng,

Yu‐Jen Fang

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

Citations

8
Reply to comment on “Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program” DOI Creative Commons
Hung‐Wei Wang, Cheng‐Yuan Peng, Ming‐Lung Yu

et al.

Journal of the Formosan Medical Association, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
The Triglyceride-Glucose Index as a Biomarker for Insulin Resistance Following Hepatitis C Virus Eradication: A Prospective Cohort Study DOI Open Access

Shih-Hsiung Shen,

Hsin‐Ju Tsai,

Yu‐Hsuan Li

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 2963 - 2963

Published: April 25, 2025

Background: The triglyceride-glucose (TyG) index has emerged as a novel surrogate marker of insulin resistance, but its changes after hepatitis C virus (HCV) eradication remain unclear. This study aimed to evaluate in the TyG following direct-acting antiviral (DAA) treatment. Methods: HCV-infected patients achieving sustained virological response 12 weeks post-treatment (SVR12) were prospectively enrolled from May 2015 June 2023. Exclusion criteria included following: (1) failure achieve SVR12; (2) use anti-diabetes or anti-hyperlipidemia medications; and (3) B human immunodeficiency co-infection. Changes lipid profiles, index, homeostasis model assessment resistance (HOMA-IR) evaluated baseline SVR12. Insulin was defined HOMA-IR ≥ 2.5. optimal cut-off for predicting determined using Youden Index. Results: A total 111 (median age: 61.0 years; 45.9% male) included. correlated positively with (Pearson’s r = 0.32, p < 0.001). Among pre-existing significant improvements observed at SVR12 both (4.0 [IQR: 3.1–5.4] vs. 2.5 2.0–3.9]; 0.001) (8.47 8.08–8.68] 8.36 8.00–8.71]; 0.028). Using 8.27 cut-off, similar noted (2.8 2.0–4.3] 2.3 1.5–3.8]; 0.031) (8.62 8.46–8.83] 8.52 8.27–8.89]; 0.003). Conclusions: is valuable tool monitoring HCV eradication, particularly resistance.

Language: Английский

Citations

0
The Impact of Liver Steatosis on Interleukin and Growth Factors Kinetics during Chronic Hepatitis C Treatment DOI Open Access
Leona Radmanić, Snježana Židovec Lepej,

Nikolina Salek

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(16), P. 4849 - 4849

Published: Aug. 16, 2024

Background/Objectives: Various biological response modifiers play important roles in the immunopathogenesis of chronic hepatitis C (CHC). While serum levels cytokines and growth factors change with disease severity treatment responses, impact concomitant liver steatosis on systemic inflammatory is largely unknown. The aim this study was to analyze characteristics kinetics profiles interleukins CHC patients steatotic (SLD). Methods: Serum concentrations 12 (IL-5, IL-13, IL-2, IL-6, IL-9, IL-10, IFN-γ, TNF-α, IL-17A, IL-17F, IL-4 IL-22) 6 (Angiopoietin-2, EGF, EPO, HGF, SCF, VEGF) were analyzed 56 at four time points (baseline, week 4, 8 SVR12) bead-based flow cytometry assay. Results: At baseline, SLD had significantly lower IL-13 IL-22 higher VEGF ANG. In a subgroup advanced fibrosis, linked IL-4, IL-5, HGH VEGF. Distinct cytokine during DAA observed, identified as main source variation for IL-22, Patients SVR12 HGF concentrations. Conclusions: associated distinct factor treatment, which might be capacity regeneration contribute fibrosis persistence.

Language: Английский

Citations

0